So far, the PK of CFTR modulators was assessed in normal, healthy animals, with no additional assessments conducted in the infected models (26, 27), indicating a gap between clinical manifestations of CF disease and preclinical studies. This evidence concerns the gene CFTR and cystic fibrosis.